Παραπομπή APA

Wright, K. D., Zimmerman, M. A., Fine, E., Aspri, T., Kieran, M. W., & Chi, S. (2018). LGG-26. TYPE II BRAF INHIBITOR TAK-580 SHOWS PROMISE FOR UPCOMING CLINAL TRIAL AS EVIDENCED BY SINGLE PATIENT IND STUDY. Neuro Oncol.

Παραπομπή Chicago Style

Wright, Karen D., Mary Ann Zimmerman, Elizabeth Fine, Tristan Aspri, Mark W. Kieran, και Susan Chi. "LGG-26. TYPE II BRAF INHIBITOR TAK-580 SHOWS PROMISE FOR UPCOMING CLINAL TRIAL AS EVIDENCED BY SINGLE PATIENT IND STUDY." Neuro Oncol 2018.

Παραπομπή MLA

Wright, Karen D., et al. "LGG-26. TYPE II BRAF INHIBITOR TAK-580 SHOWS PROMISE FOR UPCOMING CLINAL TRIAL AS EVIDENCED BY SINGLE PATIENT IND STUDY." Neuro Oncol 2018.

Πρόσοχή: Οι παραπομπές μπορεί να μην είναι 100% ακριβείς.